Endocrine Abstracts

Background: The optimal therapy sequencing for metastatic neuroendocrine tumors (NETs) remains undefined. Recent advances in systemic therapies may have changed approaches. Better understanding in patterns of care is necessary to assess and design treatment strategies. We examined the use of factors associated with liver-directed therapy over time.Methods: We conducted a population-based study of metastatic NETs over 2000-2019. Outcomes were use of liver...

Background: While there have been major advances in the care of neuroendocrine tumors (NETs), there is still no widely adopted therapeutic sequencing in metastatic NETs. The roles and benefits of locoregional treatments need reassessment, in order to define a modern therapeutic algorithm. We examined contemporary short-term outcomes of liver-directed therapy for metastatic NETs.Methods: We conducted a population-based retrospective cohort study of patien...

Background: While the epidemiology of overall and gastrointestinal neuroendocrine neoplasms (NENs) has been reported, data specific to lung NENs remain scarce. Such understanding is crucial in designing tailored strategies to improve care and outcomes. We examined the incidence, overall survival (OS), and disease-specific death (DS-deaths) for lung NENs.Methods: We conducted a population-based retrospective cohort study of adult patients with incident lu...

Background: 177Lu-DOTATATE is an FDA and Health Canada-approved treatment option for metastatic, progressive GEPNET patients. 177Lu-DOTATATE is now often considered the treatment of choice for small bowel/midgut patients who have progressed on somatostatin analogs (SSA). Despite 177Lu- DOTATATE’s impressive disease stabilization, many patients will eventually progress. Progression after prior use of PRRT does not necessarily render these tumors resistant to future PRRT tr...

Background: The treatment of neuroendocrine neoplasms (NENs) of higher grade remains a dilemma. In these patients the role of immunotherapy is still unclear and predictive biomarkers are an unmet need. Herein, we present a revised translational analysis of the NET001 and NET002 (NCT03278405, NCT03278379) clinical trials.Methods: Patients with advanced WHO G2-3 NENs who had a gastroenteropancreatic (GEP) or a bronchial primary (excluding typical carcinoid...

Background: Carcinoid heart disease (CHD) is a complication of neuroendocrine tumors (NETs). While its pathophysiology and manifestations are described, little is known about its occurrence in all patients diagnosed with NETs. We examined the occurrence of CHD and explored the use of echocardiography after diagnosis of NET.Methods: We conducted a population-based retrospective cohort study of adults diagnosed with small bowel and lung NETs (2000-2019). C...

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...